Overall Type-specific HPV positivity (% b ) HPV positivit y (% a ) Others (type) N=0 (0%) N=0 (0%) N=2

Transcription

1 Overall Type-specific y (% b ) Löning et al (1988), Germany Crook et al (1991), UK Scholefield et al (1991), UK Palefsky et al (1991), ISH 6b, 11, 16 & 18. SB & E7 for 16&18 Alkaline hydrolisis, & PCR DNA probes for 16 ISH and PCR primers for 6/11, 16, 18, 31, 33 & 35. FISH 2 Verrucous (84%) 252 N=93 (37%) 5 Adenocarcinomas 6 Carcinoma in situ (33.3%) 13 1 (84.6%) 8 (90.5%) (9.5%) N=93 (18.2%) 0 (91.0%) (6&11) (2.4%) Fresh samples. Samples from UK (43% 16+), Brazil (47% 16+), India (3% 16+), Poland (19% 16+), South Africa (11% 16+) & Switzerland (19% 16+). (27.3 %) (9.0%) Zaki et al (1992), Ogunbiyi et al. (1994), UK Holm et al (1994), Norway ISH for 6/11, 16/18, 31/35/51 & PCR primers for 6, 11, 16, 18 & 33 E6/E7 primers for 16 ISH and PCR primers for 6/11, 16, 18, 11 N=8 (72.7%) 5 74 in women 6 (89%) 31 & in men 4 (56%) (12.5%) (12.5%) (37.5%) (12.5%) (37.5%) (12.5%) 2 (93.9%) 3 (92.9%) (3%) N=8 (12.1%) (7.1%) (9.1%) 1

2 Overall Type-specific y (% b ) Noffsinger et al (1995), Canada, China & Shroyer et al (1995), Williams et al (1996), UK 5 Welldifferentiated Vincent- Salomon et al (1996), France ISH for 6/11, 16/18, 31/33/35 & PCR primers for 6, 16, 18 PCR MY09/11 and SBH (6, 11, 16, 18, 31 & 33) ISH for 6/11,16/18 SBH for 6/11/42, 16/18/33, 31/35/39 and PCR specific for 6/11, 16, 18, moderately differentiated 12 poorly differentiated 13 Basaloid 2 In situ carcinomas 6 (46.4%) 11 Basaloid 0 (90.9%) 16 Non-basaliod 8 margin anal carcinomas 27 canal anal carcinomas 18 Keratinizing 2 (75%) 2 (81.5%) 2 (66.7%) 9 Basaloid N=8 (88.9%) 1 in situ Carcioma 1 Paget's disease (11.5%) 9 (13.1%) (15.4%) (1 6/18) N=7 (70%) (7.7%) (10%) (16.7%) 0 (83.3%) (16.7%) 2 2 N=5 (62.5%) (3.8%) (6 & 16) (3.8%) (16 & 18) (10%) (20%) (x) (12.5%) (x) (10%) (18.3%) (6/11&18) (18.3%) In 3 cases DNA was detected by PCR but not by ISH and in 2 other cases DNA was detected by ISH but not by PCR. 5 samples were not tested by PCR. There was no positive or negative correlation between DNA expression and ductal differenciation or neutral mucin production. A correlation between DNA and a mixed basaloid morphology vs purely (20/24, 83.3% vs 6/11, 54.5%) was found. Frozen sample of tumor tissue. 2

3 Overall Type-specific y (% b ) Ramanuja m et al (1996), Frisch et al (1997), Denmark & Sweden Poletti et al. (1998), Switzerland Lai et al. (1998), China ISH 6,11,16,18,31, 33,35 and specific genotyping for 6, 11, 16, 18, 31 & 33 PU-1M (Fujinaga 91) for HR 16, 18, 31, 33, 52 & 58. PU-31B (Fujinaga 91) for LR 6 & 11 PCR MY09/11 and DBH (6, 11, 16, 18 & 33) 26 anal SC N=8 (30.7%) 27 perianal SC 0 (37%) 324 (262 and 62 in situ in women) 93 (87 and 6 in situ in men) 82/3 04 (92.7%) N=58/84 (69%) 33 3 (39.4%) 19 (5%) 8 Cloagenic 23 Adenocarcinoma 6 Adenosquamous Carcinoma 16 Other types of Carcinoma N=8 (60%) (40%) (1.1%) (3.4%) 35 (83.3%) 8 (6.4%) 8 (82.7%) (6.9%) (1.1%) 0 (7.1%) (5.2%) N=8 (2.8%) (40, 42, 43 & 44) (5.2%) (40, 42, 43 & 44) (7.69%) 2 (92.3%) (16/18/31/33/52/58) 10 of these patients (26.3%) had also cervical (some cervical carcinomas) associated with. 23 rectal adenocarcinomas also tested. 3

4 Overall Type-specific y (% b ) Frisch et al. (1999), Denmark & Sweden (HR 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68) and (LR 6, 11, 40, 42, 43 & 44). -typing for 16, 18, 31 & Women & anal canal and perianal skin cancer 67 Heterosexual men & anal canal and perianal skin cancer 11 Homosexual men & anal canal and perianal skin cancer (*) N=56/222 Women perianal skin cancer 28 (90%) 8 (58%) (87%) 9 (7%) (1%) 6 (6%) N=5 (2%) (1%) (1.4%) (18%33) (*) 5/54 Heterosexual men perianal skin cancer (46%) N=7 (28%) Indinnimeo et al. (1999), Italy PCR for 6/11, 16, 18, 31/33 7 N=5 (71.4%) 7 Cloacogenic (57.1%) (40%) (60%) Fresh samples. Women and heterosexual men. 4

5 Overall Type-specific y (% b ) Youk et al. (2001), Korea Daling et al. (2004), Daling et al. (2004), MY09/11, L1C1/L1C2 and Type specific for 16&18 MY09/11 for 6/11, 16, 18/45, 31 MY09/11 for 6/11, 16, 18/45, Cloacogenic 81 in men (45.25%) 98 in women (54.75%) 6 Cloagenic/Basaloi d in men (14.6%) 35 Cloagenic/Basaloi d in women (85.4%) 8 Adenocarcinoma in men (40%) 12 Adenocarcinoma in women (60%) 3 Basal cell Carcinoma in men (73%) 1 Basal cell Carcinoma in woman 1 Melanoma (Man) 2 Kaposi Sarcoma (Men) 1 N=75 (92.6%) N=90 (91.8%) 4 (97.1%) (66.7%) 1 Sarcoma (Man) 1 3 (84%) (8%) N=73 (81.1%) 0 (11.1%) 3 (97%) (33.3%) 14 heterosexual male, 7 female. 34 control samples, all negative. Only data for 16 and 18 shown. 13 samples were from the rectum (0 (77%) +), 73 samples were from the anal canal (7 (91.8%) +), 19 samples were from the anus NOS (6 (84.2%) +), 73 samples were from the Anorectum (4 (87.7%) +) and 70 samples were from the skin (1 (87.1%) +). 5

6 Overall Type-specific y (% b ) Varnai et al. (2006), Germany Kagawa et al. (2006), Japan. Tachezy et al. (2007), Czeck Republic Laytragoon -Lewin et al. (2007), Sweden and MY09/11 PCR and genotyping for 6, 11, 16, 18, 31, 33, 42, 52 & 58. ISH and typespecific genotyping PCR MY09/11 & GP5+/6+ 13 Male Anal 34 Female Anal 8 (80.9% ) 3 in men 5 in women 10 N=8 8 Basaloid (75%) 4 Basaloid & Squamous mix 5 Tubulary Adenocarcinoma 56 female anal 16 male anal (20% ) 5 (90.3%) 5 (92.1%) (2.6%) N=8 N=50 (77%) 5 (38.5%) (2.6% ) (7.9%) (3%) (2.6%) (45 ) (2.6%) (16&31) (2.6%) (16&33) (2.6%) (18&45) Initially were 20 samples (9 men and 11 women) 2 (18.5%) a. percentages given are percentages of positives among all samples. b. percentages given are percentages of types among positives cases. 6